Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401027 | 0.84 | CYP1A2 (0.46) | CYP1A2RAB9AL3MBTL1TSHRLMNA | |
| SCHEMBL1401008 | 0.80 | CYP1A2 (0.44) | CYP1A2RAB9AL3MBTL1TSHRLMNA | |
| SCHEMBL7282328 | 0.78 | CYP1A2 (0.40) | CYP1A2RAB9AL3MBTL1TSHRLMNA | |
| SCHEMBL4959764 | 0.77 | CYP1A2 (0.41) | CYP1A2RAB9AL3MBTL1TSHRALOX5 | |
| SCHEMBL31325279 | 0.69 | CYP1A2 (0.59) | CYP1A2RAB9ATSHRALOX5ALDH1A1 | |
| SCHEMBL31357582 | 0.69 | CYP1A2 (0.59) | CYP1A2RAB9ATSHRALOX5ALDH1A1 | |
| SCHEMBL1477937 | 0.69 | CYP1A2 (0.50) | CYP1A2RAB9AL3MBTL1TSHRLMNA | |
| SCHEMBL9235430 | 0.69 | CYP1A2 (0.46) | CYP1A2RAB9AL3MBTL1TSHRPOLB | |
| SCHEMBL1401271 | 0.69 | DNM1 (0.46) | L3MBTL1TSHRLMNAALDH1A1USP2 | |
| SCHEMBL4618714 | 0.68 | CYP1A2 (0.57) | CYP1A2RAB9AL3MBTL1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1173177-B2 | USE OF MACROLIDE COMPOUNDS FOR THE TREATMENT OF DRY EYE | SUCAMPO AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-8551522-B2 | Sustained-release formulation | ASTELLAS PHARMA INC. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2198858-B1 | Sustained release preparation of a macrolide compound like tacrolimus | ASTELLAS PHARMA INC (JP) | 2011-06-29 | — | — | EP | disclosed |
| EP-1064942-B9 | SUSTAINED RELEASE PREPARATION OF A MACROLIDE | FUJISAWA PHARMACEUTICAL CO (JP) | 2011-03-02 | — | — | EP | disclosed |
| EP-1421939-B9 | Sustained release preparation of a macrolide compound like tacrolimus | ASTELLAS PHARMA INC (JP) | 2011-03-02 | — | — | EP | disclosed |
| EP-2198858-A1 | Sustained release preparation of a macrolide compound like tacrolimus | Astellas Pharma Inc. (JP) | 2010-06-23 | — | — | EP | disclosed |
| EP-1421939-B1 | Sustained release preparation of a macrolide compound like tacrolimus | ASTELLAS PHARMA INC (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20090074858-A1 | SUSTAINED-RELEASE FORMULATION | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20080207670-A1 | Dermally Applicable Formulations For Treating Skin Diseases in Animals | BAYER HEALTHCARE AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1791522-A1 | DERMALLY APPLICABLE FORMULATIONS FOR TREATING SKIN DISEASES IN ANIMALS | Bayer HealthCare AG (DE) | 2007-06-06 | — | — | EP | disclosed |
| WO-1992019278-A1 | USE OF MACROLIDE COMPOUNDS FOR EYE DISEASES | KURUME UNIVERSITY (JP) | 1992-11-12 | — | — | WO | disclosed |
| WO-1992013862-A1 | LACTONE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-20 | — | — | WO | disclosed |
| US-5110811-A | Antibody inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| WO-1991019495-A1 | USE OF A MACROLIDE COMPOUND SUCH AS FK 506 FOR MANUFACTURING A MEDICAMENT FOR TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA AND BASEDOW'S DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-26 | — | — | WO | disclosed |
| WO-1991017754-A1 | METHODS FOR TREATING AND PREVENTING INFLAMMATION OF MUCOSA AND BLOOD VESSELS USING FK 506 AND RELATED COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-28 | — | — | WO | disclosed |
| EP-0444659-A2 | A pharmaceutical solution comprising derivatives of FK506 | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-04 | — | — | EP | disclosed |
| EP-0428169-A2 | Aqueous liquid formulations | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-22 | — | — | EP | disclosed |
| EP-0423714-A2 | Hair revitalizing agent | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-24 | — | — | EP | disclosed |
| EP-0406791-A2 | Aqueous liquid composition for external use | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-09 | — | — | EP | disclosed |
| US-4929611-A | ANTIBODY INHIBITORS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074858-A1 | SUSTAINED-RELEASE FORMULATION | ABCB11, SLC38A7, ABCG2 | CYP1A2 1104/4885RAB9A 1827/4885L3MBTL1 4458/4885 |
| US-20080207670-A1 | Dermally Applicable Formulations For Treating Skin Diseases in Animals | KRT18, CUTA, PIGS | CYP1A2 425/4885RAB9A 4258/4885L3MBTL1 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.